A Phase III Randomized, Open-Label Study of Docetaxel in Combination With CG1940 and CG8711 Versus Docetaxel and Prednisone in Taxane-Naive Patients With Metastatic Hormone-Refractory Prostate Cancer With Pain

Trial Profile

A Phase III Randomized, Open-Label Study of Docetaxel in Combination With CG1940 and CG8711 Versus Docetaxel and Prednisone in Taxane-Naive Patients With Metastatic Hormone-Refractory Prostate Cancer With Pain

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Docetaxel (Primary) ; Prednisone (Primary) ; Tumour cell vaccine-GVAX (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms VITAL-2
  • Sponsors Cell Genesys
  • Most Recent Events

    • 26 Feb 2009 Preliminary results were presented at ASCO Genitourinary Cancer Symposium 2009.
    • 27 Aug 2008 Status changed from recruiting to discontinued according to a Cell Genesys media release.
    • 23 Jul 2008 On track to complete enrolment in the first half of 2009 according to cell Genesys media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top